Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma

Abstract

BackgroundPancreatic carcinoma (PC) is one of the most aggressive cancers affecting human health. It is essential to identify candidate biomarkers for the diagnosis and prognosis of PC. The present study aimed to investigate the diagnosis and prognosis biomarkers of PC.MethodsDifferentially expressed genes (DEGs) were identified from the mRNA expression profiles of GSE62452, GSE28735 and GSE16515. Functional analysis and the protein-protein interaction network analysis was performed to explore the biological function of the identified DEGs. Diagnosis markers for PC were identified using ROC curve analysis. Prognosis markers were identified via survival analysis of TCGA data. The protein expression pattern of the identified genes was verified in clinical tissue samples. A retrospective clinical study was performed to evaluate the correlation between the expression of candidate proteins and survival time of patients. Moreover, comprehensive analysis of the combination of multiple genes/proteins for the prognosis prediction of PC was performed using both TCGA data and clinical data. In vitro studies were undertaken to elaborate the potential roles of these biomarkers in clonability and invasion of PC cells.FindingsIn total, 389 DEGs were identified. These genes were mainly associated with pancreatic secretion, protein digestion and absorption, cytochrome P450 drug metabolism, and energy metabolism pathway. The top 10 genes were filtered out following Fisher's exact test. ROC curve analysis demonstrated that TMPRSS4, SERPINB5, SLC6A14, SCEL, and TNS4 could be used as biomarkers for the diagnosis of PC. Survival analysis of TCGA data and clinical data suggested that TMC7, TMPRSS4, SCEL, SLC2A1, CENPF, SERPINB5 and SLC6A14 can be potential biomarkers for the prognosis of PC. Comprehensive analysis show that a combination of identified genes/proteins can predict the prognosis of PC. Mechanistically, the identified genes attributes to clonability and invasiveness of PC cells.InterpretationWe synthesized several sets of public data and preliminarily clarified pathways and functions of PC. Candidate molecular markers were identified for diagnosis and prognosis prediction of PC including a novel gene, TMC7. Moreover, we found that the combination of TMC7, TMPRSS4, SCEL, SLC2A1, CENPF, SERPINB5 and SLC6A14 can serve as a promising indicator of the prognosis of PC patients. The candidate proteins may attribute to clonability and invasiveness of PC cells. This research provides a novel insight into molecular mechanisms as well as diagnostic and prognostic markers of PC.Fund [No. 81602646 & 81802339], [No. 2016A030310254] and [No. 2016M600648].

Identification and validation of a ten-gene set variation score as a diagnostic and prognostic stratification tools in hepatocellular carcinoma

“…Not surprisingly, we found that some of these genes were reported and associated with cancer. In HCC-unfavorable gene set, STEAP1B, TMC7, CYP19A1 and PNCK associated with prostate cancer, pancreatic carcinoma, breast cancer, respectively [16][17][18][19]. Here, we found them may also be associated with HCC.…”

Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients

“…Interestingly CENPF and SERBINB5 were also included in this panel of prognostic genes. Both of these genes were also identified in our panel [51]. SLC6A14 has been investigated as a potential novel therapeutic target for pancreatic cancer using α-methyltryptophan as a pharmacological inhibitor of SLC6A14 and showed reduced proliferation and clonogenic survival [52].…”

Development and clinical validation of A Novel 9-gene prognostic biomarkers based on multi-omics in pancreatic adenocarcinoma

“…After referring to previously published literature, we selected four prognostic risk models, including 15gene signature (Chen) [21], 7-gene signature (Cheng) [22], 5-gene signature (Raman) [23], and 9-gene signature (Wu) [24] for the comparison with our 9-genes model. To ensure comparability, we calculated the risk score of each PAAD sample in the TCGA using the same method based on the corresponding genes in the 4 models, and evaluated the ROC of each model, and divided the samples into Risk-H and Risk-L groups in accordance with the median risk score.…”

“…Chen et al constructed a 15-gene signature to predict the prognosis of patients with early pancreatic ductal cancer [21]. Cheng et al constructed a 7-gene signature for the prognosis of pancreatic cancer based on multiple GEO cohorts [22]. In addition, the 5-gene signature was constructed by by Raman et al…”